- Home
- OTLK vs RDNW Comparison
OTLK vs RDNW Comparison
Compare OTLK & RDNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | RDNW |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 227.8M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OTLK | RDNW |
|---|---|---|
| Price | $0.66 | $5.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $2.50 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 21.2M | 65.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | 37.84 |
| EPS | N/A | ★ 0.06 |
| Revenue | $8,146,123.00 | ★ $1,793,369,000.00 |
| Revenue This Year | $1,430.98 | $9.01 |
| Revenue Next Year | $173.23 | $6.53 |
| P/E Ratio | ★ N/A | $92.00 |
| Revenue Growth | N/A | ★ 91.10 |
| 52 Week Low | $0.16 | $3.20 |
| 52 Week High | $2.54 | $8.55 |
Technical Indicators
Market Signals| Indicator | OTLK | RDNW |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 34.80 |
| Support Level | $0.60 | $5.25 |
| Resistance Level | $0.94 | $6.23 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 53.36 | 15.71 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RDNW RideNow Group Inc.
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.